Clinical Trials

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05941741 2026-03-18

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Nasopharyngeal Carcinoma

NCT06029270 2026-03-18

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

156 enrolled

Nasopharyngeal Carcinoma

NCT06064097 2026-03-18

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

50 enrolled

Nasopharyngeal Carcinoma

NCT01612351 2026-03-17

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Phase 2 Completed

40 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03485209 2026-03-16

innovaTV 207

GastrointestinalHead & NeckThoracic

352 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04083599 2026-03-16

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

266 enrolled

Nasopharyngeal Carcinoma

NCT01810913 2026-03-13

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

613 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07219212 2026-03-13

LUMIRAY

Phase 1 Recruiting

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06959082 2026-03-11

Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

30 enrolled

Head and Neck Cancer Squamous Cell Carcinoma

NCT04030455 2026-03-09

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT05491512 2026-03-09

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

121 enrolled

Oropharyngeal Neoplasms

NCT07209189 2026-03-09

(NeoScorch HN)

75 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05721755 2026-03-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

290 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07327216 2026-03-04

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

180 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

403 enrolled 10 charts

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT05050162 2026-03-03

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Phase 2/3 Suspended

1,714 enrolled

Carcinoma, Oropharyngeal Neoplasms

NCT06208826 2026-03-03

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

268 enrolled

Head and Neck Neoplasms

NCT02031250 2026-03-02

Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer

Phase 2 Completed

106 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT02734537 2026-03-02

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

189 enrolled

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT05681039 2026-03-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

29 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06457503 2026-03-02

TRANSPARENT

Phase 4 Recruiting

100 enrolled

Nasopharyngeal Neoplasms

NCT07026474 2026-03-02

RePaIr-HN

214 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT00003809 2026-02-27

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Phase 3 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07435311 2026-02-27

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Phase 1 Completed

118 enrolled

Phase 3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07435324 2026-02-27

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

161 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04620187 2026-02-24

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

55 enrolled

Salivary Gland Neoplasms

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

GastrointestinalHead & Neck

39 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05268614 2026-02-18

Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma

250 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03822897 2026-02-17

EVADER

103 enrolled 11 charts

Oropharyngeal Neoplasms

NCT05075980 2026-02-13

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

174 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lymphatic Metastasis, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms, Salivary Gland Neoplasms

NCT06557889 2026-02-11

REDUCE

86 enrolled

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07392580 2026-02-06

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

20 enrolled

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07393477 2026-02-06

Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03040999 2026-02-04

KEYNOTE-412

Phase 3 Completed

804 enrolled 20 charts

Phase 3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

412 enrolled

Nasopharyngeal Neoplasms

NCT06532279 2026-02-02

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

98 enrolled